Evidence map›Paper›PMID 35396760›Full record

ArticleJournal of applied microbiology2022

CLEVER assay: A visual and rapid RNA extraction-free detection of SARS-CoV-2 based on CRISPR-Cas integrated RT-LAMP technology.

Akansha Bhatt, Zeeshan Fatima, Munindra Ruwali, Chitra Seetharam Misra, Shyam Sunder Rangu, Devashish Rath, Ashok Rattan, Saif Hameed

Open access · bronzeAbstract read
In one paragraph

Article in Journal of applied microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. CRISPR-assisted MoSMikrochimica acta · 2025
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. CRISPR-Cas-Integrated LAMP.Biosensors · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Akansha BhattAmity Institute of Biotechnology, Amity University Haryana, Gurugram, Haryana, India.
Zeeshan FatimaAmity Institute of Biotechnology, Amity University Haryana, Gurugram, Haryana, India.
Munindra RuwaliAmity Institute of Biotechnology, Amity University Haryana, Gurugram, Haryana, India.
Chitra Seetharam MisraCRISPR Biology Group, Applied Genomics Section, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Shyam Sunder RanguCRISPR Biology Group, Applied Genomics Section, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Devashish RathCRISPR Biology Group, Applied Genomics Section, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India.
Ashok RattanPathkind Labs, Gurugram, Haryana, India.
Saif HameedAmity Institute of Biotechnology, Amity University Haryana, Gurugram, Haryana, India.ORCID https://orcid.org/0000-0002-6477-1870
Bhabha Atomic Research Centre · IN

Funding

Board of Research in Nuclear Sciences BRNS/37080
6 · The paper itself

Abstract

aimThe current scenario of COVID-19 pandemic has presented an almost insurmountable challenge even for the most sophisticated hospitals equipped with modern biomedical technology. There is an urgency to develop simple, fast and highly accurate methods for the rapid identification and isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. To address the ongoing challenge, the present study offers a CLEVER assay (CRISPR-Cas integrated RT-LAMP Easy, Visual and Extraction-free RNA) which will allow RNA extraction-free method to visually diagnose COVID-19. RNA extraction is a major hurdle in preventing rapid and large-scale screening of samples particularly in low-resource regions because of the logistics and costs involved. METHOD AND

resultHerein, the visual SARS-CoV-2 detection method consists of RNA extraction-free method directly utilizing the patient's nasopharyngeal and oropharyngeal samples for reverse transcription loop-mediated isothermal amplification (RT-LAMP). Additionally, the assay also utilizes the integration of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas12-based system using different guide RNAs of N, E and an internal control POP7 (human RNase P) genes along with visual detection via lateral flow readout-based dip sticks with unaided eye (~100 min). Overall, the clinical sensitivity and specificity of the CLEVER assay were 89.6% and 100%, respectively.

conclusionTogether, our CLEVER assay offers a point-of-care tool with no equipment dependency and minimum technical expertise requirement for COVID-19 diagnosis. SIGNIFICANCE AND IMPACT OF THE STUDY: To address the challenges associated with COVID-19 diagnosis, we need a faster, direct and more versatile detection method for an efficient epidemiological management of the COVID-19 outbreak. The present study involves developing a method for detection of SARS-CoV-2 in human body without RNA isolation step that can visually be detected with unaided eye. Taken together, our assay offers to overcome one major defect of the prior art, that is, RNA extraction step, which could limit the deployment of the previous assays in a testing site having limited lab infrastructure.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingCRISPR-Cas SystemsHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPandemicsRNARNA, ViralSensitivity and SpecificityTechnologyRNARNA, ViralCOVID-19CRISPR-Cas12lateral flow readoutRNART-LAMPSARS-CoV-2

Identifiers

PMID35396760
PMCPMC9111511
OpenAlexW4223415312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.